, Tracking Stock Market Picks
Enter Symbol:
Poniard Pharmaecuticals, Inc. (PARD) [hlAlert]

down 99.94 %

Poniard Pharmaecuticals, Inc. (PARD) rated Buy

Posted on: Wednesday,  Oct 3, 2007  9:25 AM ET by Credit Suisse

Credit Suisse rated Buy Poniard Pharmaecuticals, Inc. (OTCBB: PARD) on 10/03/2007, when the stock price was $235.20. Since
then, Poniard Pharmaecuticals, Inc. has lost 99.95% as of 08/27/2015's recent price of $0.12.
If you would have followed this Credit Suisse's recommendation on PARD, you would have lost 99.94% of your investment in 2885 days.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors. The Company initiated a Phase III SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in small cell lung cancer. The Company is also conducting separate Phase I/II studies of picoplatin in the treatment of patients with metastatic colorectal cancer and hormone-refractory prostate cancer. NeoRx Manufacturing Group, Inc. is a wholly owned subsidiary of the Company.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/3/2007 9:25 AM Buy
235.20 400.00
as of 8/27/2015
1 Week up  50.00 %
1 Month up  9.09 %
3 Months up  71.42 %
1 YTD down  -58.62 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy